Neuland laboratories has announced that its Board of Directors will convene on February 9, 2026, to approve the company's unaudited financial results for the third quarter of fiscal year 2026. The pharmaceutical company made this announcement on January 21, 2026, in compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The scheduled board meeting will focus on approving and taking on record the unaudited financial results for both standalone and consolidated operations. The results will cover the quarter and nine months ended December 31, 2025.

Trading Window Restrictions

In accordance with the company's Insider Trading Code, Neuland Laboratories has implemented trading window restrictions for its equity shares. The trading window closure, which began on January 1, 2026, will remain in effect until 48 hours after the declaration of the unaudited financial results to the stock exchanges.

This measure ensures compliance with insider trading regulations and maintains market integrity during the financial results announcement period. The company had previously communicated about these restrictions in a letter dated December 26, 2025.

Regulatory Compliance

The announcement demonstrates Neuland Laboratories' commitment to maintaining transparency and adhering to regulatory requirements. Company Secretary Sarada Bhamidipati signed the official communication, which was addressed to both BSE Limited and The National Stock Exchange of India Ltd.

The notification serves as formal intimation to stakeholders about the upcoming financial disclosure and ensures all regulatory protocols are followed in accordance with SEBI guidelines.

Neuland Laboratories has reported a substantial increase in its export performance, with revenues reaching $20.4 million, representing a remarkable 143% growth on a month-on-month basis. This significant achievement underscores the pharmaceutical company's strengthening position in international markets.

Export Performance Highlights

The company's export business has demonstrated exceptional momentum with this substantial growth figure. The month-on-month comparison reveals the company's ability to rapidly scale its international operations and capitalize on global market opportunities.

Business Impact

This export performance reflects Neuland Laboratories' operational capabilities and market positioning in the pharmaceutical sector. The substantial increase in export revenues indicates strong demand for the company's products in international markets and effective execution of its global business strategy.

The 143% month-on-month growth represents a significant milestone for the company's international business segment, demonstrating its ability to meet growing global demand and expand its market reach effectively.